There are 749 resources available
Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients
Presenter: Chia-Hsun Hsieh
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Slides
Webcast
Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Presenter: Michael Friedlander
Session: Proffered paper session - Gynaecological cancers
Resources:
Slides
Prevalence of germline BRCA1 and BRCA2 mutations and variants among ovarian, primary peritoneal and fallopian tube cancer patients: A multicentre Indian study
Presenter: Sudeep Gupta
Session: Proffered paper session - Gynaecological cancers
Resources:
Slides
Presentation of case/condition
Presenter: Sanjay Popat
Session: Challenges in the management of clinical stage N2 disease
Resources:
Slides
Webcast
Medical oncologist’s perspective
Presenter: Enriqueta Felip
Session: Challenges in the management of clinical stage N2 disease
Resources:
Slides
Webcast
Radiation oncologist’s perspective
Presenter: Yong Chan Ahn
Session: Challenges in the management of clinical stage N2 disease
Resources:
Slides
Webcast
Thoracic surgeon’s perspective
Presenter: Tetsuya Mitsudomi
Session: Challenges in the management of clinical stage N2 disease
Resources:
Slides
Webcast
LBA10 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Presenter: Keiichi Fujiwara
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Slides
LBA11 - Mainstreaming genetic counselling for genetic testing of BRCA1/2 in ovarian cancer patients in Malaysia (MaGIC study)
Presenter: Sook Yee Yoon
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Slides
LBA14 - Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
Presenter: Afaf Abed
Session: Mini Oral session - Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast